Axim Biotechnologies, Inc.
AXIM- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001514946
No open-market purchases or sales by Axim Biotechnologies, Inc. insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026
- 0
- 13F valueReported value at the end of Q2 2026
- $0
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding AXIM, Q2 2026
No superinvestor reported holding AXIM at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Axim Biotechnologies, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 15, 2024 (view filing) | Jan 30 | 259 daysLate | Valencia CatalinaPresident and Director | PPurchase | +1.09M | – | – | +3.9%28.6M after | |
| Sep 23, 2022 (view filing) | Mar 19, 2020 | 918 daysLate | Huemoeller John Walter IIChief Executive Officer | PPurchase | +6.00M | – | – | New position6.00M after | |
| Aug 31, 2022 (view filing)4:01 PM ET | Aug 24 | 7 daysLate | Valencia Catalina10% Owner | PPurchase | +3.86M | $0.0259 | +$100.0K | +19.5%23.7M after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Axim Biotechnologies, Inc. at the end of Q2 2026; share changes are against Q1 2026.
No institution reported holding AXIM in 13F filings for Q2 2026.